RYTM — Rhythm Pharmaceuticals, Inc. stock price, charts and financials
QT45Rhythm Pharmaceuticals, Inc.Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -3.13 | Insider Own | 1.50% | Shs Outstand | 68.59M | Perf Week | -2.79% |
| Market Cap | 6.81B | Forward P/E | - | EPS next Y | -0.68 | Insider Trans | -6.69% | Shs Float | 55.67M | Perf Month | -10.11% |
| Enterprise Value | 6.97B | PEG | 2.60 | EPS next Q | - | Inst Own | - | Short Float | 17.20% | Perf Quarter | 21.99% |
| Income | -204.24M | P/S | 31.35 | EPS this Y | 0.05% | Inst Trans | - | Short Ratio | 11.97 | Perf Half Y | -4.29% |
| Sales | 217.16M | P/B | 54.89 | EPS next Y | 78.19% | ROA | -45.82% | Short Interest | 9.57M | Perf YTD | -7.28% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -203.25% | 52W High | 126.55 -18.78% | Perf Year | 17.23% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -56.40% | 52W Low | 77.15 33.22% | Perf 3Y | 462.64% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 99.30% - | Gross Margin | 89.41% | Volatility | 5.14% 3.92% | Perf 5Y | 395.75% |
| Dividend TTM | - | EV/Sales | 32.11 | EPS Y/Y TTM | 27.88% | Oper. Margin | -90.89% | ATR (14) | 4.59 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.89 | Sales Y/Y TTM | 66.92% | Profit Margin | -93.33% | RSI (14) | 40.83 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.17 | EPS Q/Q | -2.47% | SMA20 | -7.67% | Beta | 1.89 | Target Price | 141.33 |
| Payout | 0.00% | Debt/Eq | 1.85 | Sales Q/Q | 81.82% | SMA50 | -0.72% | Rel Volume | 0.55 | Prev Close | 99.25 |
| Employees | 414 | LT Debt/Eq | 1.71 | Earnings | Aug 04 | SMA200 | 0.23% | Avg Volume | 807.63K | Price | 102.78 |
| IPO Date | Oct 09, 2017 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -0.96% 7.77% | Net Debt/EBITDA | -0.91 | Volume | 447,071 | Change | 3.56% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-07-26 | Reiterated | RBC Capital | Outperform | $145 → $141 |
| Jun-16-26 | Reiterated | Canaccord Genuity | Buy | $143 → $151 |
| Jun-15-26 | Reiterated | Stifel Nicolaus | Buy | $131 → $133 |
| Jun-15-26 | Reiterated | Wells Fargo | Overweight | $143 → $155 |
| May-07-26 | Reiterated | Canaccord Genuity | Buy | $141 → $143 |
| Mar-12-26 | Reiterated | Telsey Advisory | $143 | |
| Mar-12-26 | Reiterated | Wells Fargo | Overweight | $145 → $143 |
| Mar-03-26 | Reiterated | Jefferies | $80 → $125 | |
| Feb-26-26 | Reiterated | Stifel Nicolaus | Buy | $78 → $131 |
| Feb-18-26 | Reiterated | RBC Capital | $145 |
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 217 | 190 | 130 | 77 | 24 | 3 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 23 | 19 | 13 | 9 | 2 | 1 | 1 | 1 | 0 | |
| Gross Profit | 194 | 170 | 117 | 68 | 22 | 3 | -1 | -1 | 0 | |
| Selling, General and Administrative Excl. Other | 219 | 195 | 144 | 118 | 92 | 68 | 46 | 37 | 28 | |
| Research and Development | 172 | 167 | 238 | 135 | 109 | 104 | 90 | 109 | 50 | |
| Other Operating Expense | 0 | 0 | 0 | -1 | 0 | 1 | 0 | -1 | 0 | |
| Operating Income | -197 | -192 | -266 | -184 | -179 | -170 | -137 | -146 | -78 | |
| Interest Expense | 21 | 21 | 21 | 14 | 5 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 16 | 17 | 26 | 14 | 3 | 100 | 3 | 5 | 4 | |
| Net Income Before Taxes | -202 | -196 | -260 | -184 | -181 | -70 | -134 | -141 | -74 | |
| Income Taxes | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -204 | -197 | -261 | -185 | -181 | -70 | -131 | -135 | -74 | |
| Net Income From Continuing Operations | -204 | -197 | -261 | -185 | -181 | -70 | -134 | -141 | -74 | |
| Net Income | -204 | -197 | -261 | -185 | -181 | -70 | -131 | -135 | -74 | |
| EPS (Recurring) | -3.13 | -3.11 | -4.34 | -3.20 | -3.51 | -1.37 | -2.96 | -3.70 | -2.39 | |
| EPS (Basic, Before Extraordinaries) | -3.13 | -3.11 | -4.34 | -3.20 | -3.51 | -1.37 | -2.96 | -3.70 | -2.39 | |
| EPS (Diluted) | -3.13 | -3.11 | -4.34 | -3.20 | -3.51 | -1.37 | -2.96 | -3.70 | -2.39 | |
| EBITDA | -181 | -174 | -238 | -168 | -174 | -68 | -136 | -145 | -78 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 32.21 | 36.62 | 26.27 | 34.63 | 63.09 | 166.33 | — | — | — | |
| Gross Margin | 89.40 | 89.47 | 90.00 | 88.31 | 91.67 | 100.00 | — | — | — | |
| Operating Margin | -90.78 | -101.05 | -204.62 | -238.96 | -745.83 | -5,666.67 | — | — | — | |
| Net Margin | -94.01 | -103.68 | -200.77 | -240.26 | -754.17 | -2,333.33 | — | — | — | |
| Shares Outstanding | 68 | 65 | 61 | 58 | 52 | 50 | 44 | 36 | 31 | |
| Market Capitalization | 6,989 | 6,958 | 3,415 | 2,666 | 1,514 | 499 | 1,308 | 827 | 833 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Garfield Alastair | Chief Scientific Officer | Jul 01 '26 | Option Exercise | 0.00 | 4,445 | 0 | 12,208 | Jul 02 |
| Arbuckle Stuart A | Director | Jun 23 '26 | Option Exercise | 0.00 | 4,712 | 0 | 11,712 | Jun 25 |
| JEAN CHRISTOPHE | Director | Jun 23 '26 | Option Exercise | 0.00 | 4,712 | 0 | 11,712 | Jun 25 |
| TETRAULT LYNN A. | Director | Jun 23 '26 | Option Exercise | 0.00 | 4,712 | 0 | 11,712 | Jun 25 |
| MCGIRR DAVID W J | Director | Jun 23 '26 | Option Exercise | 0.00 | 4,712 | 0 | 11,712 | Jun 25 |
| GOOD JENNIFER L | Director | Jun 23 '26 | Option Exercise | 0.00 | 4,712 | 0 | 11,712 | Jun 25 |
| TETRAULT LYNN A. | Director | Jun 22 '26 | Sale | 100.32 | 37,000 | 3,711,896 | 7,000 | Jun 24 |
| TETRAULT LYNN A. | Director | Jun 22 '26 | Option Exercise | 28.27 | 37,000 | 1,045,990 | 44,000 | Jun 24 |
| Smith Hunter C | Chief Financial Officer | May 18 '26 | Option Exercise | 17.87 | 3,000 | 53,610 | 119,611 | May 20 |
| German Christopher Paul | Corporate Controller & CAO | May 15 '26 | Option Exercise | 42.17 | 4,442 | 187,313 | 4,643 | May 19 |
| German Christopher Paul | Corporate Controller & CAO | May 15 '26 | Sale | 92.21 | 4,643 | 428,131 | 0 | May 19 |
| Mazabraud Yann | EVP, Head of International | Apr 01 '26 | Option Exercise | 0.00 | 25,750 | 0 | 66,030 | Apr 03 |
| German Christopher Paul | Corporate Controller & CAO | Mar 04 '26 | Option Exercise | 17.97 | 1,500 | 26,955 | 5,753 | Mar 06 |
| German Christopher Paul | Corporate Controller & CAO | Mar 04 '26 | Sale | 89.56 | 5,614 | 502,790 | 160 | Mar 06 |
| German Christopher Paul | Corporate Controller & CAO | Mar 01 '26 | Option Exercise | 0.00 | 1,162 | 0 | 4,595 | Mar 03 |